Technetium-99M labeled peptides for imaging inflammation

Details Technetium-99M labeled peptides for imaging inflammation Technetium-99M labeled peptides for imaging inflammation

1997-07-29

1999-12-07

Dees, Jose' G.

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

424 111, 424 165, 530300, 530324, 530325, 530326, 530327, 530328, 530329, 530330, 534 10, 534 14, A61K 5100, A61M 3614

Patent

active

059978457

ABSTRACT:
This invention relates to radiolabeled scintigraphic imaging agents, and methods and reagents for producing such agents. Specifically, the invention relates to specific binding compounds, including peptides, that bind to a platelet receptor that is the platelet GPIIb/IIIa receptor, methods and kits for making such compounds, and methods for using such compounds labeled with technetium-99m via a covalently-linked radiolabel-binding moiety to image thrombi in a mammalian body.

REFERENCES:
patent: 4434151 (1984-02-01), Byrne et al.
patent: 4444690 (1984-04-01), Fritzberg et al.
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4571430 (1986-02-01), Byrne et al.
patent: 4575556 (1986-03-01), Byrne et al.
patent: 4578079 (1986-03-01), Rouslhati et al.
patent: 4729525 (1988-03-01), Rouslhati et al.
patent: 4857508 (1989-08-01), Adams et al.
patent: 4861869 (1989-08-01), Nicolotti et al.
patent: 4986979 (1991-01-01), Morgan et al.
patent: 5086069 (1992-02-01), Klein et al.
patent: 5225181 (1993-07-01), Srivastava et al.
patent: 5256559 (1993-10-01), Maraganore et al.
patent: 5372933 (1994-12-01), Zamarron et al.
patent: 5395609 (1995-03-01), Stuttle
patent: 5492890 (1996-02-01), Ginsberg et al.
patent: 5498499 (1996-03-01), Flow et al.
patent: 5612311 (1997-03-01), Pierschbacher et al.
patent: 5645815 (1997-07-01), Dean et al.
patent: 5662885 (1997-09-01), Pollak et al.
patent: 5686571 (1997-11-01), Scarborough et al.
patent: 5830856 (1998-11-01), Dean et al.
Rhodes, 1974, "Considerations in the Radiolabeling of Albumin", Sem. Nucl. Med. 4: 281-293.
Davidson et al., 1981, "A New Class of Oxotechnetium(5+) Chelate Complexes containing a TcON.sub.2 S.sub.2 Core", Inorg. Chem. 20: 1629-1632.
Fritzberg et al., 1982, "Synthesis and Biological Evaluation of Tc-99m N,N'-Bis(mercaptoacetyl)-2,3-diaminopropanoate: A Potential Replacement for [.sup.131 I]0-iodohippurate", J. Nucl. Med. 23: 592-598.
Fritzberg et al., 1982, "Clinical comparison of Tc-99m N,N'-bis(mercaptoacetamido)ethylenediamine and (.sup.131 I)ortho-iodohippurate for evaluation of renal tubular function: Concise Communication", J. Nucl. Med. 23: P17.
Khaw et al., 1982, "Technetium-99m Labeling of Antibodies to Cardiac Myosin Fab and to Human Fibrinogen", J. Nucl. Med. 23: 1011-1019.
Byrne and Tolman, 1983, "Technetium-99m Bifunctional Chelating Agent--Thiolactone for Coupling to Biomolecules, N.sub.2 S.sub.2 Ligand for Chelation to Technetium", J. Nucl. Med. 24: P126.
Bryson et al., 1988, "Neutral Technetium(V) Complexes with Amide-Thiol-Thioether Chelating Ligands", Inorg. Chem. 27: 2154-2161.
Bryson et al., 1990, "Protecting Groups in the Preparation of Thiolate Complexes of Technetium", Inorg. Chem. 29: 2948-2951.
Knight et al., 1990, "Thrombus Imaging with Tc-99m Synthetic peptides Reactive with Activated Platelets", J. Nucl. Med. 31: 757 #209.
Deuel et al., 1977, Proc. Natl. Acad. Sci. USA 74: 2256-2258 disclose the amino acid sequence of human platelet factor 4.
Niedel and Cuatrecasas, 1980, Formyl Peptide Chemotactic Receptors of Leukocytes and Macrophages, in Curr. Top. Cell. Reg. 17: 137-170 disclose that formyl-methionyl-leucyl-phenylalanyl peptides cause superoxide release from neutrophils.
Deuel et al., 1981, Proc. Natl. Acad. Sci. USA 78: 4584-4587 disclose that platelet factor 4 is chemotactic for neutrophils and monocytes in vitro.
Zoghbi et al., 1981, J. Nucl. Med. 22: 32 (Abst) disclose formyl peptide chemotactic factors (fMLF) derived from bacteria coupled to .sup.111 In-labeled transferrin.
Jiang et al., 1982, Nuklearmedizin 21: 110-113 disclose a chemotactic formylated peptide (fMLF) radiolabeled with .sup.125 I.
Osterman et al., 1982, Biochem. Biophys. Res. Comm. 107: 130-135 disclose that the carboxyl-terminal tridecapeptide of platelet factor 4 has chemotactic properties.
Holt & Niewiarowski, 1985, Sem. Hematol. 22: 151-163 provide a review of the biochemistry of platelet .alpha.-granule proteins, including platelet factor 4.
Goldman et al., 1985, Immunol. 54: 163-171 reveal that fMLF receptor-mediated uptake is inhibited in human neutrophils by platelet factor 4 and a carboxyl-terminal dodecapeptide thereof.
Loscalzo et al., 1985, Arch. Biochem. Biophys. 240: 446-455 describe the biochemical interaction between platelet factor 4 and glycosaminoglycans such as heparin.
Bebawy et al., 1986, J. Leukocyte Biol. 39: 423-434 describe the platelet factor 4-mediated chemotactic response of neutrophils in vitro.
Wilkinson, 1988, Meth. Enzymol. 162: 127-132 discloses a method for characterizing chemotactic peptides capable of causing leukocytes to move up a peptide concentration gradient.
Vorne et al., 1989, J. Nucl. Med. 30: 1332-1336 disclose the use of Tc-99m labeled leukocytes for imaging sites of infection.
LaMuraglia et al., 1989, J. Vasc. Surg. 10: 20-28 disclose the use of .sup.111 In-labeled non-specific human immunoglobulin to detect sites of inflammation in vivo.
Maione et al., 1989, Science 247: 77-79 disclose that angiogenesis is inhibited by recombinant human platelet factor 4 and peptide fragments thereof.
Lind et al., 1990, J. Nucl. Med. 31: 417-473 disclose the use of Tc-99m labeled antigranulocyte monoclonal antibodies to detect inflammation.
Fischman et al., 1991, J. Nucl. Med. 32: 482-491 relates to chemotactic formyl peptide (fMLF)--.sup.111 In-labeled DTPA conjugates.
Hartman et al., 1992, "Non-peptide fibrinogen receptor antagonists: 1. Discovery and design of exosite inhibitors", J. Med. Chem. 35: 4640-4642.
Ojima et al., 1992, "Design and Synthesis of New RGD Peptides as Inhibitors of Human Platelet Aggregation", 204th Meeting, Amer. Chem. Soc. Abst. 44.
Knight, 1990, "Radiopharmaceuticals for Thrombus Detection", Sem. Nucl. Med. 20: 52-67.
Plow et al., 1987, in Perspectives in Inflammation, Neoplasia and Vascular Cell Biology, pp. 267-275.
Pearson et al (1996), J. Med. Chem, vol.39, No. 7, pp. 1372-1382, Thrombus Imaging Using Technetium-99m Labeled High Potency GPIIb/IIIa Receptor Antagonists. Chemistry and Initial Biological Studies.

Affiliated with

Also associated with

Rating

Technetium-99M labeled peptides for imaging inflammation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Technetium-99M labeled peptides for imaging inflammation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Technetium-99M labeled peptides for imaging inflammation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-820452